by Brenda Baletti, Ph.D., Childrens Health Defense:
French scientist Hélène Banoun, Ph.D., author of the preprint study that analyzed outcomes from the 2023-2024 RSV immunization campaign in four countries, found a “significant increase in mortality” among newborns between 2 and 6 days of age in France. Banoun’s findings suggest that antibody-dependant enhancement may be to blame.
TRUTH LIVES on at https://sgtreport.tv/
The results from the first immunization campaign for nirsevimab, the monoclonal antibody shot approved to protect infants from RSV-related illness, raise questions about mass infant vaccination with the drug, according to a new preprint study.
The study by French scientist Hélène Banoun, Ph.D., which analyzed outcomes from the 2023-2024 respiratory syncytial virus (RSV) immunization campaign in the U.S., France, Spain and Luxembourg, contradicts some claims of success by U.S. public health agencies and medical associations.
In France in particular, Banoun told The Defender, “a significant increase in mortality among newborns between 2 and 6 days of age was observed from the start of the campaign: babies were injected before leaving the maternity ward.”
Deaths from nirsevimab also have been identified elsewhere. In clinical trials for the drug, 12 infants died. However, a spokesperson for the U.S. Food and Drug Administration (FDA) told CNBC when the drug was approved that “none of the deaths appeared to be related to nirsevimab.”
Yet according to Banoun’s study, both the FDA and the European Medicines Agency (EMA) noted a slightly higher death rate in treated groups in clinical trials of the drug, although the number of deaths was low.
Earlier this week, The Defender reported that documents obtained through a Freedom of Information Act from the Centers for Disease Control and Prevention (CDC) showed at least two infant deaths reported to the Vaccine Adverse Event Reporting System (VAERS) were linked to Beyfortus, the brand name for nirsevimab.
Regarding the increase in mortality, Banoun told The Defender, “All this was to be expected, and was undoubtedly due to the antibody-dependent-enhancement, or ADE, known to affect RSV antibodies, particularly those directed against the RSV F surface protein,” the viral protein targeted by RSV drugs.
Read More @ ChildrensHealthDefense.org
